InfuSystem (INFU) Q2 2025 earnings summary

Executive summary

• Net revenues for Q2 2025 reached a record $36.0 million, up 7% year-over-year, with both Patient Services and Device Solutions contributing to growth.

• Net income increased 262% to $2.6 million, with EPS at $0.12, and adjusted EBITDA rose 32% to $8.0 million.

• Gross margin expanded to 55.2%, and operating cash flow more than doubled to $8.8 million year-to-date.

• Returned $3.5 million to shareholders via stock repurchases in Q2, totaling $6.4 million for the first half.

• Strategic focus on profitable growth, operational efficiency, and disciplined capital allocation.

Financial highlights

• Gross profit was $19.9 million, up 19% year-over-year, with gross margin improving to 55.2%.

• Adjusted EBITDA margin expanded to 22.3% from 18% a year ago.

• Operating cash flow for the first half was $8.8 million, up from $2.7 million in the prior year.

• Net capital expenditures for Q2 were $273K, down from $6.7 million last year; H1 2025 capex was $4.3 million, down 51%.

• Interest expense decreased to $0.4 million in Q2 2025 due to lower average debt balances.

Outlook and guidance

• 2025 revenue growth outlook revised to 6–8% (from 8–10%) due to delayed wound care rollout, Chemo Mouthpiece forecast removal, and GE Healthcare contract restructuring.

• Full-year adjusted EBITDA margin guidance raised by 120 basis points to 20% or higher.

• ERP system investment of ~$2.5 million in 2025 to be completed by Q1 2026; expected to become a margin tailwind post-implementation.

• Oncology and Wound Care expected to deliver mid-single-digit growth going forward.

• No material impact is expected from recently enacted U.S. tax legislation (OBBBA) in Q3 2025.